Literature DB >> 9356739

The benefit of hormone replacement therapy on bone mass is greater at the vertebral body than posterior processes or proximal femur.

Y Duan1, A Tabensky, V DeLuca, E Seeman.   

Abstract

The aim of this study was to determine whether the higher vertebral bone mass in women receiving hormone replacement therapy (HRT) is confined to the trabecular rich vertebral body rather than the predominantly cortical posterior processes, and to determine whether the protective effect of HRT at the proximal femur, a predominantly cortical site, is less than at the spine. Bone mass (g) of the third lumbar vertebra (total, vertebral body and posterior processes, measured by lateral scanning), and bone mineral density (g/cm2) of the femoral neck, Ward's triangle, and trochanter were measured using dual X-ray absorptiometry in a cross-sectional study of 71 women receiving HRT for 5.7 +/- 0.4 years (mean +/- SEM), ranging from 1 to 21 years, 69 age-matched controls, and 42 premenopausal controls aged 20 to 40 years. Relative to untreated postmenopausal controls, total bone mass of the third lumbar vertebra (body plus posterior processes) by postero-anterior (PA) scanning was 0.4 +/- 0.1 SD or 9.6 +/- 3.0% higher in HRT treated women (p < 0.01). By lateral scanning, total bone mass was higher than age-matched controls (z score 0.4 +/- 0.1 SD or 11.2 +/- 3.4%, p < 0.01). This difference was confined to the vertebral body (z score 0.6 +/- 0.1 SD, p < 0.001), which was 17.1 +/- 3.3% higher than in age-matched controls (p < 0.001). Bone mass of the posterior processes was no higher [z score 0.1 +/- 0.1, not significant (NS)]. The deficit at the vertebral body in HRT-treated women, relative to premenopausal controls, was half the deficit at the vertebral body in untreated postmenopausal women (t score -0.7 +/- 0.1 vs. -1.4 +/- 0.1 SD, respectively; p < 0.001) but no less at the posterior processes (t score -1.6 +/- 0.2 vs. -1.9 +/- 0.2 SD, respectively; NS). Similarly, the deficit in the vertebral body in the HRT treated group was half the deficit at their posterior processes (t score -0.7 +/- 0.1 SD vs. -1.6 +/- 0.2, respectively; p < 0.001). In HRT-treated women, bone mass diminished significantly with age at the posterior processes (r = -0.31, p < 0.01), but not at the vertebral body (r = -0.21, p = 0.07). Bone mass diminished significantly with age at the vertebral body and posterior processes in untreated women (r = -0.55, p < 0.001; r = -0.45, p < 0.001, respectively). Bone density (g/cm2) diminished at all femoral sites with advancing age in HRT-treated women. A protective effect was seen at the femoral neck and Ward's triangle, but not trochanter (z score 0.2 +/- 0.1, p = 0.06; 0.3 +/- 0.1, p < 0.05; 0.0 +/- 0.1, NS, respectively). In conclusion, the protective effect of HRT against bone loss at the vertebral body, the site of fracture in osteoporosis, may be underestimated by PA scanning. The greater benefit at the vertebral body, and more modest effect at the proximal femur, suggests that HRT may be a more effective means of reducing the risk of spine than hip fractures.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9356739     DOI: 10.1016/s8756-3282(97)00177-4

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  9 in total

1.  Polymorphisms in the estrogen receptor beta (ESR2) gene are associated with bone mineral density in Caucasian men and women.

Authors:  Shoji Ichikawa; Daniel L Koller; Munro Peacock; Michelle L Johnson; Dongbing Lai; Siu L Hui; C Conrad Johnston; Tatiana M Foroud; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2005-08-23       Impact factor: 5.958

2.  Association of a T262C transition in exon 1 of estrogen-receptor-alpha gene with skeletal responsiveness to estrogen in post-menopausal women.

Authors:  B Ongphiphadhanakul; S Chanprasertyothin; P Payattikul; S Saetung; N Piaseu; L Chailurkit; S Chansirikarn; G Puavilai; R Rajatanavin
Journal:  J Endocrinol Invest       Date:  2001-11       Impact factor: 4.256

3.  Differential effects of hormone replacement therapy on bone mineral density and axial transmission ultrasound measurements in cortical bone.

Authors:  K M Knapp; G M Blake; T D Spector; I Fogelman
Journal:  Osteoporos Int       Date:  2003-04-15       Impact factor: 4.507

4.  Evaluation of bone remodeling with (18)F-fluoride and correlation with the glucose metabolism measured by (18)F-FDG in lumbar spine with time in an experimental nude rat model with osteoporosis using dynamic PET-CT.

Authors:  Caixia Cheng; Christian Heiss; Antonia Dimitrakopoulou-Strauss; P Govindarajan; G Schlewitz; Leyun Pan; Reinhard Schnettler; Klaus Weber; Ludwig G Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-03-08

5.  Evaluation of new bone formation in normal and osteoporotic rats with a 3-mm femur defect: functional assessment with dynamic PET-CT (dPET-CT) using 2-deoxy-2-[(18)F]fluoro-D-glucose ( (18)F-FDG) and (18)F-fluoride.

Authors:  Caixia Cheng; Volker Alt; Antonia Dimitrakopoulou-Strauss; Leyun Pan; Ulrich Thormann; Reinhard Schnettler; Klaus Weber; Ludwig G Strauss
Journal:  Mol Imaging Biol       Date:  2013-06       Impact factor: 3.488

6.  Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone.

Authors:  Edward P Weiss; Krupa Shah; Luigi Fontana; Charles P Lambert; John O Holloszy; Dennis T Villareal
Journal:  Am J Clin Nutr       Date:  2009-03-25       Impact factor: 7.045

7.  PLCL1 rs7595412 variation is not associated with hip bone size variation in postmenopausal Danish women.

Authors:  Stéphane Cauchi; Inger Byrjalsen; Emmanuelle Durand; Morten A Karsdal; Philippe Froguel
Journal:  BMC Med Genet       Date:  2009-12-23       Impact factor: 2.103

8.  The 18 kDa translocator protein (peripheral benzodiazepine receptor) expression in the bone of normal, osteoprotegerin or low calcium diet treated mice.

Authors:  Winnie Wai-Ying Kam; Steven R Meikle; Hong Zhou; Yu Zheng; Julie M Blair; Marcus Seibel; Colin R Dunstan; Richard B Banati
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

9.  Bone Matrix Levels of Dickkopf and Sclerostin are Positively Correlated with Bone Mass and Strength in Postmenopausal Osteoporosis.

Authors:  Thor Ueland; Lis Stilgren; Jens Bollerslev
Journal:  Int J Mol Sci       Date:  2019-06-14       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.